Eikon Therapeutics is a late clinical-stage biotechnology company that has not yet generated revenue from product sales and continues to incur substantial net losses. The filing highlights the development of its lead product candidates, including EIK1001 and EIK1003, and notes a restatement of financial statements for the nine months ended September 30, 2025, due to a material weakness in internal controls.
Eikon Therapeutics reported third quarter 2026 financial results, ending the period with $461.7 million in cash and extending its projected runway into Q1 2028. The company highlighted clinical progress in its oncology portfolio, including the dosing of the first patient in a registrational Phase 2/3 trial for EIK1001 and the submission of an IND for its prostate cancer candidate EIK1006.
Term
Q3 2026
“The third quarter was marked by important progress across Eikon’s oncology programs. At the 2026 ESMO Congress, we presented updated results from TeLuRide-005, providing additional evidence of durable anti-tumor activity for EIK1001 in combination with standard-of-care therapy in squamous NSCLC, building on earlier data in non-squamous NSCLC that we shared at ASCO.”
Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair
Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.
Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.
“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”
Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon